Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows in line with its trailing trend

Q1 FY2026 selling, general & admin of $6.84M rose 23.3% year over year, in line with the +23.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 4.6% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.

Context

  • Selling, general & admin amounted to 38813.6% of revenue in FY2025, up 34904.0 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 12 analysts of $87.66M (+282.8%) for the fiscal year ending Dec 2026, a step up from the +32.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.84M+4.6% QoQ
Last fiscal yearDec 2025
$22.9M+32.8% YoY
LTMMar 2026
$24.19M+23.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.3%-100.0%-123.3 pp
1 year+32.8%+282.8%+250.0 pp
3-year CAGR+3.4%-62.4%-65.8 pp
5-year CAGR+230.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
22.9M USD
Year-over-year change
+32.8%
4-year CAGR
-1.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.5% is the 5th highest of 10, against a peer median of +5.5%.
  • Selling, general & admin amounts to 41000.0% of revenue for AVTX, versus a peer median of 64.5%.
AVTX Competitors
Selling, General & Admin for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$65.29M USD+5.1%+10.3%62.2%
ANABAnaptysBio, Inc.LTM Mar 2026$62.81M USD+42.2%+11.5%27.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$60.45M USD+31.0%+18.9%66.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$24.19M USD+23.5%+3.4%41000.0%
IMUXImmunic, Inc.LTM Mar 2026$23.53M USD+30.1%+11.7%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M USD+5.5%-4.4%269.8%
QTTBQ32 Bio Inc.LTM Mar 2026$17.08M USD-4.8%+20.7%31.8%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$16.54M USD-15.6%+10.2%—
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€9.82M EUR+63.8%——
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —+5.5%+10.9%64.5%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.